Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer

NCT01069640 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides

Sponsor

Shiga University

Collaborators

[object Object]